NEW YORK (GenomeWeb News) – Sigma-Aldrich said today that it will make and market oligonucleotides developed by Polyplus-transfection, a Strasbourg, France-based firm, under a new worldwide license agreement.
The agreement covers Polyplus-transfection's Zip Nucleic Acid (ZNA) oligonucleotides, which are designed for use in research and diagnostic applications.
ZNA oligonucleotides have attached cationic units that increase their sensitivity and ability to detect mutations. They are used in PCR probes and primers, siRNA, and in vitro micro RNA detection, Sigma-Aldrich said.
"The increased performances seen for ZNA oligonucleotides offer advantages for our customers, and we look forward to making this technology available to our global customer base," Sigma Custom Products VP Theresa Creasey said in a statement.
Financial terms of the agreement were not released.